Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01352637 · ClinicalTrials.gov registry record · Phase 3
Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
NCT01352637 is a Phase 3 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 192 participants.
The verdict
NCT01352637, a Phase 3 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
Study Summary
The purpose of this study is to test the differences between four active treatment conditions for combat-related Post Traumatic Stress Disorder (PTSD): virtual reality exposure therapy (VRE) or prolonged imaginal exposure therapy (PE), both with DCS or placebo, as well as to examine predictors for PTSD and response to treatment in active duty military personnel, veterans, and civilians who served in Iraq and Afghanistan.
Interventions
- DRUG DCS (D-Cycloserine ) + Prolonged Imaginal Exposure
- DRUG DCS (D-Cycloserine ) + Virtual Reality Exposure
- DRUG Placebo + Prolonged Imaginal Exposure
- DRUG Placebo (sugar pill) + Virtual Reality Exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2011-05 |
| Est. Completion | 2018-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01352637
The ClinicalTrials.gov registry entry for NCT01352637 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which DCS (D-Cycloserine ) + Prolonged Imaginal Exposure is the first listed.
NCT01352637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01352637 about?
NCT01352637 is a clinical study titled "Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer". The purpose of this study is to test the differences between four active treatment conditions for combat-related Post Traumatic Stress Disorder (PTSD): virtual reality exposure therapy (VRE) or prolonged imaginal exposure therapy (PE), both with DCS or placebo, as well as to examine predictors for P...
What is the current status of trial NCT01352637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2011-05. Estimated completion is 2018-09.
What interventions are being tested in trial NCT01352637?
The interventions under investigation include: DCS (D-Cycloserine ) + Prolonged Imaginal Exposure (DRUG), DCS (D-Cycloserine ) + Virtual Reality Exposure (DRUG), Placebo + Prolonged Imaginal Exposure (DRUG), Placebo (sugar pill) + Virtual Reality Exposure (DRUG).
Who is sponsoring clinical trial NCT01352637?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.